Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells ...

Octreotide scintigraphy versus DOTATOC PET: Concordance of Krenning scores and implications on PRRT treatment eligibility. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

-- First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort -- -- Management hosting webcast and conference call today at 1:30 p.m. ET / 10 ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ...

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...

A new study published online in the Journal of Intensive Medicine on June 17, 2025, highlights early and dynamic alterations in lymphocyte subsets following sepsis in elderly patients and their ...

ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable residual disease (MRD)-negative responses in the first four patients with relapsed ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

-- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort -- ...

AbCellera today announced new data on its PSMA x CD3 T-cell engagers, presented as a poster at the American Association for Cancer ResearchⓇ 116th Annual Meeting at the McCormick Place Convention ...